Disease Progression

DefinitionNLM MeSH D018450

The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Source: U.S. National Library of Medicine — MeSH (Disease Progression)

Drugs reporting Disease Progression (235)

Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.

1. 1Malvin1100%
2. 2Sacituzumab1,24229%
3. 3Tafasitamab23026%
4. 4Dyclonine2826%
5. 5Denileukin Diftitox125%
6. 6Polatuzumab Vedotin1,97222%
7. 7Belinostat7021%
8. 8Datopotamab Deruxtecan8820%
9. 9Margetuximab519%
10. 10Tazemetostat30019%
11. 11Idelalisib1,22517%
12. 12Glofitamab35517%
13. 13Pemigatinib13617%
14. 14Tipiracil1,79517%
15. 15Zenocutuzumab117%
16. 16Trifluridine1,81217%
17. 17Futibatinib3016%
18. 18Ensartinib414%
19. 19Mosunetuzumab11414%
20. 20Nitazoxanide4514%
21. 21Tebentafusp7113%
22. 22Dextran 40913%
23. 23Vitamin K2212%
24. 24Verteporfin17312%
25. 25Vinorelbine76511%
26. 26Eflornithine411%
27. 27Azurite111%
28. 28Cornsilk111%
29. 29Piperine111%
30. 30Elacestrant78011%
31. 31Retifanlimab411%
32. 32Pralatrexate6911%
33. 33Streptozocin2411%
34. 34Temsirolimus47911%
35. 35Sotorasib32911%
36. 36Bendamustine2,74810%
37. 37Sunitinib3,90610%
38. 38Ifosfamide2,08910%
39. 39Dextran 70110%
40. 40Elivaldogene Autotemcel110%
41. 41Crizotinib1,2159.7%
42. 42Lurbinectedin1019.7%
43. 43Malate3,9129.5%
44. 44Avelumab3719.4%
45. 45Dordaviprone49.3%
46. 46Gemcitabine4,7539.2%
47. 47Temozolomide1,8749.1%
48. 48Mogamulizumab1138.9%
49. 49Tivozanib1348.7%
50. 50Imlunestrant28.7%
51. 51Axicabtagene Ciloleucel7858.3%
52. 52Nilutamide68.2%
53. 53Loncastuximab Tesirine288.0%
54. 54Zongertinib57.7%
55. 55Cemiplimab1437.6%
56. 56Miglustat857.5%
57. 57Entrectinib1157.1%
58. 58Zanubrutinib2737.1%
59. 59Tagraxofusp357.1%
60. 60Doxorubicin6,5957.1%
61. 61Thalidomide2,4916.9%
62. 62Neratinib1546.8%
63. 63Capecitabine6,0096.7%
64. 64Telisotuzumab36.7%
65. 65Topotecan4496.6%
66. 66Pirtobrutinib466.6%
67. 67Lapatinib9996.5%
68. 68Tovorafenib176.5%
69. 69Vemurafenib7666.4%
70. 70Taletrectinib36.4%
71. 71Platinum656.3%
72. 72Carmustine2876.3%
73. 73Axitinib1,2116.3%
74. 74Pentetreotide86.3%
75. 75Etoposide4,5526.2%
76. 76Tepotinib356.1%
77. 77Sodium Tetradecyl Sulfate36.1%
78. 78Siltuximab366.0%
79. 79Cisplatin4,5906.0%
80. 80Bevacizumab7,4755.9%
81. 81Oxaliplatin4,2335.9%
82. 82Ripretinib2905.8%
83. 83Obinutuzumab8995.7%
84. 84Ibritumomab Tiuxetan855.6%
85. 85Lomustine1395.6%
86. 86Atezolizumab2,0765.5%
87. 87Trastuzumab4,7755.5%
88. 88Irinotecan6755.5%
89. 89Indium85.4%
90. 90Trabectedin1225.4%
91. 91Indocyanine Green65.3%
92. 92Pralsetinib895.2%
93. 93Gefitinib4585.1%
94. 94Cabazitaxel1725.0%
95. 95Tisagenlecleucel2194.9%
96. 96Carboplatin5,9574.9%
97. 97Edaravone714.8%
98. 98Panitumumab7124.8%
99. 99Interleukin-10174.8%
100. 100Interleukin-11174.8%
101. 101Interleukin-3174.8%
102. 102Interleukin-5174.8%
103. 103Mirvetuximab Soravtansine694.7%
104. 104Quizartinib264.7%
105. 105Ceritinib1114.7%
106. 106Methoxsalen354.7%
107. 107Pertuzumab1,4354.7%
108. 108Cytarabine2,8114.6%
109. 109Cyclophosphamide7,9254.6%
110. 110Ivosidenib884.6%
111. 111Exemestane9664.6%
112. 112Erlotinib5664.6%
113. 113Zanidatamab24.5%
114. 114Vandetanib804.5%
115. 115Potassium Bicarbonate314.5%
116. 116Capivasertib1064.5%
117. 117Sipuleucel-t2494.5%
118. 118Riluzole934.5%
119. 119Mechlorethamine994.4%
120. 120Tucatinib2954.4%
121. 121Decitabine2154.4%
122. 122Aldesleukin524.3%
123. 123Ixabepilone454.3%
124. 124Bexarotene554.3%
125. 125Fluorouracil3,1974.3%
126. 126Dacarbazine3054.2%
127. 127Larotrectinib364.2%
128. 128Duvelisib314.1%
129. 129Leucovorin7504.1%
130. 130Cholic Acid164.0%
131. 131Fulvestrant1,2924.0%
132. 132Gemtuzumab Ozogamicin1434.0%
133. 133Chlorambucil1544.0%
134. 134Revumenib274.0%
135. 135Paclitaxel3,7944.0%
136. 136Docetaxel2,5963.9%
137. 137Romidepsin643.9%
138. 138Dactinomycin843.9%
139. 139Mitotane673.9%
140. 140Pazopanib1,0073.8%
141. 141Pemetrexed1,3703.7%
142. 142Triptorelin2093.7%
143. 143Cedazuridine283.7%
144. 144Sonidegib533.6%
145. 145Linvoseltamab13.6%
146. 146Erdafitinib423.6%
147. 147Mitoxantrone2163.5%
148. 148Vincristine9993.5%
149. 149Mesna2853.4%
150. 150Telavancin43.4%
151. 151Brentuximab Vedotin3373.4%
152. 152Tamoxifen1883.3%
153. 153Letrozole1,9853.3%
154. 154Melphalan8013.2%
155. 155Radium2253.2%
156. 156Osilodrostat623.2%
157. 157Ramucirumab1933.2%
158. 158Lisocabtagene Maraleucel253.1%
159. 159Afatinib2013.1%
160. 160Mitomycin983.1%
161. 161Everolimus1,5203.0%
162. 162Belantamab823.0%
163. 163Belantamab Mafodotin823.0%
164. 164Dotatate1723.0%
165. 165Abiraterone1,1993.0%
166. 166Nitrogen32.9%
167. 167Vinblastine552.9%
168. 168Prochlorperazine1,0662.9%
169. 169Bleomycin2912.9%
170. 170Vorinostat612.9%
171. 171Alectinib2012.8%
172. 172Degarelix1442.8%
173. 173Lutetium4962.8%
174. 174Fludarabine1,0462.7%
175. 175Imiglucerase1262.7%
176. 176Defibrotide962.7%
177. 177Emapalumab52.7%
178. 178Olutasidenib72.7%
179. 179Binimetinib2012.7%
180. 180Telotristat1522.7%
181. 181Telotristat Ethyl1522.7%
182. 182Alpelisib2252.6%
183. 183Tetraxetan3222.6%
184. 184Vipivotide Tetraxetan3222.6%
185. 185Iloprost232.6%
186. 186Dexrazoxane232.6%
187. 187Resmetirom392.6%
188. 188Lusutrombopag12.6%
189. 189Ethiodized Oil322.5%
190. 190Belumosudil752.5%
191. 191Interferon Gamma-1b352.5%
192. 192Dexamethasone7,5712.5%
193. 193Laronidase992.5%
194. 194Avutometinib132.5%
195. 195Defactinib132.5%
196. 196Carfilzomib6872.5%
197. 197Ibrutinib1,9702.5%
198. 198Olaparib4922.4%
199. 199Cobimetinib1062.4%
200. 200Goserelin3172.4%
201. 201Encorafenib2302.4%
202. 202Palbociclib2,2722.4%
203. 203Venetoclax1,4332.4%
204. 204Cerliponase122.4%
205. 205Isatuximab1242.4%
206. 206Osimertinib7112.3%
207. 207Filgrastim9622.3%
208. 208Istradefylline1352.3%
209. 209Lorlatinib1482.3%
210. 210Rolapitant122.2%
211. 211Rasburicase522.2%
212. 212Tafamidis3482.2%
213. 213Azacitidine6402.2%
214. 214Talazoparib372.2%
215. 215Imatinib8912.2%
216. 216Procarbazine942.1%
217. 217Trametinib4912.1%
218. 218Capmatinib472.0%
219. 219Dabrafenib4152.0%
220. 220Naldemedine312.0%
221. 221Odevixibat62.0%
222. 222Sirolimus2521.9%
223. 223Isavuconazonium651.9%
224. 224Daratumumab7751.9%
225. 225Imetelstat31.9%
226. 226Durvalumab3351.8%
227. 227Belzutifan231.7%
228. 228Levoleucovorin601.7%
229. 229Ranibizumab4241.6%
230. 230Vutrisiran341.6%
231. 231Glasdegib71.5%
232. 232Golodirsen51.2%
233. 233Blinatumomab184—
234. 234Brigatinib115—
235. 235Brexucabtagene Autoleucel100—

Related reactions

Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.

• Malignant Neoplasm Progression103 shared · 0.37
• Neutropenia103 shared · 0.29
• Febrile Neutropenia86 shared · 0.28
• Thrombocytopenia98 shared · 0.26
• Decreased Appetite115 shared · 0.23
• Platelet Count Decreased71 shared · 0.22
• Death208 shared · 0.22
• Anaemia124 shared · 0.22
• Sepsis66 shared · 0.17
• Pyrexia160 shared · 0.17

Literature

Recent PubMed references pinned to Disease Progression as a MeSH major topic. About the reaction term itself — not about any specific drug.

• HSPB7 Deficiency Drives Aortic Aneurysm Progression in Marfan Syndrome Through Vascular Smooth Muscle Cell Phenotypic Switching.
  Clinical and experimental pharmacology & physiology · 2026 · An Z, Yan T, Ming Y, et al.
  PMID 42203489DOI 10.1111/1440-1681.70128
• CXCL14 Inhibits Colon Cancer Progression by Modulating Tumor Cell Invasion and Immune Microenvironment.
  Cells · 2026 · Zhang Y, Wang S, Niu Y, et al.
  PMID 42193871DOI 10.3390/cells15100860
• Validation and Psychometric Evaluation of the Persian Version of the Nurse Intuition Patient Deterioration Scale: A Methodological Study.
  Nursing open · 2026 · Nemati-Vakilabad R, Jafari MJ, Mirzaei A, et al.
  PMID 42184330DOI 10.1002/nop2.70616
• Variable Selection for Illness-Death Processes Under Dual Observation Schemes.
  Statistics in medicine · 2026 · Li X, Diao L, Cook RJ, et al.
  PMID 42179353DOI 10.1002/sim.70608
• AI-Based Prediction of Clinical Deterioration in Hospitalised Cardiac Patients.
  Studies in health technology and informatics · 2026 · Kang KL, Blake V, Welberry H, et al.
  PMID 42174877DOI 10.3233/SHTI260201
• Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.
  Journal of neurology · 2026 · Surcinelli A, Panzera I, Piscaglia MG, et al.
  PMID 42171804DOI 10.1007/s00415-026-13858-2